Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Elutia Inc. (ELUT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: ELUT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.1% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.93M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 2 | Beta 0.86 | 52 Weeks Range 1.61 - 5.12 | Updated Date 07/4/2025 |
52 Weeks Range 1.61 - 5.12 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -168.23% | Operating Margin (TTM) -88.72% |
Management Effectiveness
Return on Assets (TTM) -38.41% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 93589737 | Price to Sales(TTM) 3.62 |
Enterprise Value 93589737 | Price to Sales(TTM) 3.62 | ||
Enterprise Value to Revenue 3.95 | Enterprise Value to EBITDA -3.32 | Shares Outstanding 36802300 | Shares Floating 14266724 |
Shares Outstanding 36802300 | Shares Floating 14266724 | ||
Percent Insiders 2.27 | Percent Institutions 72.65 |
Upturn AI SWOT
Elutia Inc.
Company Overview
History and Background
Elutia, Inc., formerly known as Conformis, Inc., was founded in 2004. It initially focused on patient-specific orthopedic implants. Over time, it transitioned to regenerative biomaterials and resorbable polymer solutions. The company rebranded as Elutia in 2023 to reflect its broader focus.
Core Business Areas
- Regenerative Biomaterials: Elutia develops and markets a range of regenerative biomaterials used in surgical procedures, including soft tissue repair, wound management, and bone regeneration. These products leverage resorbable polymer technology.
- Resorbable Polymers: Elutia offers resorbable polymer solutions for medical device applications. They design and manufacture customized polymer materials for use in implants and other medical products.
Leadership and Structure
As of January 2024, the CEO is Terrence D. Brown. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance and operations.
Top Products and Market Share
Key Offerings
- Canalux: Canalux is a resorbable sinus spacer used in sinus surgery. Market share data is not readily available. Competitors include Stryker (SYK), Medtronic (MDT), and Johnson & Johnson (JNJ).
- SurgiBind: SurgiBind is a resorbable soft tissue scaffold used in surgical procedures to reinforce and repair soft tissues. Market share data is not readily available. Competitors include Aziyo Biologics, MTF Biologics and numerous small private companies.
Market Dynamics
Industry Overview
The regenerative medicine and biomaterials market is experiencing significant growth, driven by aging populations, increasing demand for minimally invasive procedures, and technological advancements in tissue engineering and biomaterial science.
Positioning
Elutia is positioned as a player in the regenerative medicine and biomaterials market, focusing on resorbable polymer technologies. Their competitive advantages include their proprietary polymer formulations and focus on specific surgical applications.
Total Addressable Market (TAM)
The total addressable market for regenerative biomaterials is estimated to be in the billions of dollars. Elutia's positioning targets specific sub-segments like sinus surgery and soft tissue repair.
Upturn SWOT Analysis
Strengths
- Proprietary resorbable polymer technology
- Focus on specific surgical applications
- Experienced management team
- Established distribution network
Weaknesses
- Limited market share compared to larger competitors
- Dependence on key products
- Relatively small size and resources
- Profitability not consistently demonstrated
Opportunities
- Expanding product portfolio into new surgical areas
- Strategic partnerships and acquisitions
- Increasing adoption of minimally invasive procedures
- Growth in emerging markets
Threats
- Intense competition from larger companies
- Regulatory hurdles and product approval timelines
- Pricing pressures from healthcare providers
- Potential for product liability claims
Competitors and Market Share
Key Competitors
- Stryker (SYK)
- Medtronic (MDT)
- Johnson & Johnson (JNJ)
- Aziyo Biologics (AZYO)
Competitive Landscape
Elutia faces intense competition from larger, more established medical device companies. Elutia's advantage lies in its specialized focus on resorbable polymer technologies, but it needs to expand market presence.
Major Acquisitions
None
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: No acquisitions to report.
Growth Trajectory and Initiatives
Historical Growth: Elutia has experienced fluctuations in revenue growth due to the transition from orthopedic implants to regenerative biomaterials. Historical growth figures are impacted by discontinued product lines.
Future Projections: Analyst estimates for future growth are dependent on the successful commercialization of new products and expansion into new markets. Projections vary.
Recent Initiatives: Recent strategic initiatives include rebranding the company as Elutia, focusing on regenerative biomaterials, and expanding the sales and marketing team.
Summary
Elutia Inc. is a regenerative biomaterials company undergoing a strategic shift. While they possess proprietary technology and a focused approach, they face competition from larger players. Successful commercialization of new products and market expansion are crucial for future growth. The company's financial performance and shareholder returns have been volatile in the recent past as the company transitioned to its new strategy.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (Estimates)
- Market Research Reports
Disclaimers:
This analysis is based on available information and estimates. Market conditions and company performance are subject to change. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elutia Inc.
Exchange NASDAQ | Headquaters Silver Spring, MD, United States | ||
IPO Launch date 2023-09-07 | Co-Founder, President, CEO & Director Dr. C. Randal Mills Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 51 | Website https://elutia.com |
Full time employees 51 | Website https://elutia.com | ||
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.